In summary, our results suggest that HSYA acts as a therapeutic agent to inhibit the progression of IPF, via suppressing lung fibroblast proliferation, migration, differentiation, and ECM deposition stimulated by the TGF-β1 signaling pathway. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.